Hilde Van Parijs

Summary

Affiliation: Universitair Ziekenhuis Brussel
Country: Belgium

Publications

  1. pmc Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery
    Hilde Van Parijs
    UZ Brussel, Vrije Universiteit Brussel VUB, Brussels, Belgium
    Radiat Oncol 9:36. 2014
  2. pmc Scapula alata in early breast cancer patients enrolled in a randomized clinical trial of post-surgery short-course image-guided radiotherapy
    Nele Adriaenssens
    Breast Clinic, Oncologic Surgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    World J Surg Oncol 10:86. 2012
  3. pmc Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial
    Hilde Van Parijs
    Department of Radiotherapy, UZ Brussel, Brussels, Belgium
    Radiat Oncol 7:80. 2012
  4. pmc Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy
    Harijati Versmessen
    Department of Radiation Oncology, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium
    BMC Cancer 12:495. 2012
  5. pmc Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost
    Hilde Van Parijs
    Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel VUB, Laarbeeklaan 101, 1090 Brussels, Belgium
    Biomed Res Int 2014:827475. 2014
  6. doi request reprint Dosimetric assessment of static and helical TomoTherapy in the clinical implementation of breast cancer treatments
    Truus Reynders
    Radiotherapy Department, Oncology Center, UZ Brussel, 1090 Brussels, Belgium
    Radiother Oncol 93:71-9. 2009
  7. pmc Early contralateral shoulder-arm morbidity in breast cancer patients enrolled in a randomized trial of post-surgery radiation therapy
    Nele Adriaenssens
    Breast Clinic, Oncological Surgery, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    Breast Cancer (Auckl) 6:79-93. 2012
  8. ncbi request reprint A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer
    Samuel Bral
    Department of Radiotherapy, University Hospital Brussels UZB, Brussels, Belgium
    Radiother Oncol 84:252-6. 2007

Detail Information

Publications8

  1. pmc Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery
    Hilde Van Parijs
    UZ Brussel, Vrije Universiteit Brussel VUB, Brussels, Belgium
    Radiat Oncol 9:36. 2014
    ..We present a dosimetric comparison of different non-invasive treatment techniques for additional boost delivery...
  2. pmc Scapula alata in early breast cancer patients enrolled in a randomized clinical trial of post-surgery short-course image-guided radiotherapy
    Nele Adriaenssens
    Breast Clinic, Oncologic Surgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    World J Surg Oncol 10:86. 2012
    ..We evaluated the risk factors associated with SA and the relationship of SA with ipsilateral shoulder/arm morbidity in a series of patients enrolled in a trial of post-surgery radiotherapy (RT)...
  3. pmc Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial
    Hilde Van Parijs
    Department of Radiotherapy, UZ Brussel, Brussels, Belgium
    Radiat Oncol 7:80. 2012
    ..hypofractionated Tomotherapy (TT) for post-operative treatment of breast cancer. The purpose of the trial is to compare whether TT can reduce heart and pulmonary toxicity. We evaluate early toxicities...
  4. pmc Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy
    Harijati Versmessen
    Department of Radiation Oncology, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium
    BMC Cancer 12:495. 2012
    ..Tomotherapy uses an integrated computed tomography scanner to improve treatment accuracy, aiming to reduce the adverse effects of radiotherapy...
  5. pmc Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost
    Hilde Van Parijs
    Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel VUB, Laarbeeklaan 101, 1090 Brussels, Belgium
    Biomed Res Int 2014:827475. 2014
    ..We investigated the dosimetric benefits of a simultaneously integrated boost (SIB) compared to a sequential boost to hypofractionate the boost volume, while maintaining normofractionation on the breast...
  6. doi request reprint Dosimetric assessment of static and helical TomoTherapy in the clinical implementation of breast cancer treatments
    Truus Reynders
    Radiotherapy Department, Oncology Center, UZ Brussel, 1090 Brussels, Belgium
    Radiother Oncol 93:71-9. 2009
    ..This study concentrates on the evaluation of the planning protocol for the TomoTherapy and TomoDirect TPS, dose verification and the implementation of in vivo dosimetry...
  7. pmc Early contralateral shoulder-arm morbidity in breast cancer patients enrolled in a randomized trial of post-surgery radiation therapy
    Nele Adriaenssens
    Breast Clinic, Oncological Surgery, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    Breast Cancer (Auckl) 6:79-93. 2012
    ..Shoulder/arm morbidity is a common complication of breast cancer surgery and radiotherapy (RT), but little is known about acute contralateral morbidity...
  8. ncbi request reprint A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer
    Samuel Bral
    Department of Radiotherapy, University Hospital Brussels UZB, Brussels, Belgium
    Radiother Oncol 84:252-6. 2007
    ..The 2 year infield progression free probability is 65%. Disease-specific survival is 75% at 2 years. No patients experienced grade 3-4 toxicity...